Bioventus (BVS) Liabilities from Discontinued Operations (2022)

Bioventus (BVS) reported Liabilities from Discontinued Operations of 119087000.0 for Q4 2022.

Bioventus (BVS) Liabilities from Discontinued Operations (2022) Analysis & Trends

Bioventus has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at 119087000.0 in Q4 2022.

For the quarter ending Q4 2022, Liabilities from Discontinued Operations changed N/A year-over-year to 119087000.0; the trailing twelve-month figure through Dec 2022 stood at 119087000.0 (changed N/A YoY), and the FY2022 full-year result was 119087000.0, changed N/A from the prior year.
Liabilities from Discontinued Operations for Q4 2022 stood at 119087000.0.
The five-year high for Liabilities from Discontinued Operations was 119087000.0 in Q4 2022, with the low at 119087000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn
10	Bioventus	571.68 Mn	581.20 Mn	90.77 Mn

Download Data

Date	Value
Dec 31, 2022	119.09 Mn
Dec 31, 2022	119.09 Mn